Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

BACKGROUND: Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2− breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As such, it is critical to identify the mechanisms by which resistance to CDK4/6-ba...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Neil A., McDermott, Martina S. J., Conklin, Dylan, Luo, Tong, Ayala, Raul, Salgar, Suruchi, Chau, Kevin, DiTomaso, Emmanuelle, Babbar, Naveen, Su, Faye, Gaither, Alex, Hurvitz, Sara A., Linnartz, Ronald, Rose, Kristine, Hirawat, Samit, Slamon, Dennis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427086/
https://www.ncbi.nlm.nih.gov/pubmed/32795346
http://dx.doi.org/10.1186/s13058-020-01320-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427086/
https://www.ncbi.nlm.nih.gov/pubmed/32795346
http://dx.doi.org/10.1186/s13058-020-01320-8

Ejemplares similares